Hydroxychloroquine and Phlebotomy for Treating Porphyria Cutanea Tarda
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
Porphyria cutanea tarda (PCT) is an iron-related disorder that responds to treatment by
phlebotomy or low-dose hydroxychloroquine, but comparative data on these treatments are
limited. The hypothesis is that hydroxychloroquine is noninferior to phlebotomy in terms of
time to remission. Patients with well documented PCT are assigned to treatment by
randomization if specific criteria are met. All patients are followed until remission -
defined as achieving a normal plasma porphyrin concentration.